1 mg semaglutide equivalent tirzepatide Subcutaneously administered vs for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials - Diabetologia Switching from Semaglutide to Tirzepatide:

The products are tested to make sure that there are not substances that are banned by WADA, IOC, NCAA or any corresponding authority

It is also observed in diabetes, hypertension, and chronic kidney disease, among others

This is the most critical patent expiry date, marking the earliest potential for full generic competition on the molecule itself

Accordingly, a cohort study found no association between the exposure to GLP-1R agonists and diabetic retinopathy, and in fact GLP-1R agonists were found to even decrease the risk of diabetic retinopathy by 33% when compared to new-users of insulin (Douros et al., 2018)